Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE This study aims to develop and evaluate oleuropein loaded surface functionalized folate-targeted - PEG liposomes for the effective management of prostate cancer in an animal model. 30710640 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [<sup>64</sup>Cu]-DOTHA<sub>2</sub>-PEG-RM26. 29154145 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE In the present study, a tumor-targeting cationic gene vector, known as the disulfide cross-linked arginine-aspartic acid peptide modified by HAIYPRH (T7) peptide (CRD-PEG-T7), was designed for targeted delivery of plasmid DNA (pDNA) for gene therapy of prostate cancer (PCa). 30464450 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 AlteredExpression disease BEFREE We prospectively administered a battery of geriatric (MNA, GDS, Get up and Go Test, CIRS-G, ADL, IADL, MMSE), toxicity (IPSS; IIEF 5), and QoL (QLQ C30) screening tests in 100 elderly patients before and two months after prostate cancer radiotherapy (NCT 02876237). 29630602 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE Therefore, small, short-circulating (10 kDa, ∼7 nm, t<sub>1/2</sub> ∼ 1 h) and larger, longer-circulating (40 kDa, ∼13 nm, t<sub>1/2</sub> ∼ 13 h) riboflavin-targeted branched PEG polymers were synthesized, and their biodistribution and target site accumulation were evaluated in mice bearing angiogenic squamous cell carcinoma (A431) and desmoplastic prostate cancer (PC3) xenografts. 28715227 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE Cellax polymeric conjugates consisting of carboxymethyl cellulose functionalized with PEG and hydrophobic anticancer drugs, such as cabazitaxel (coined Cellax-CBZ), have been shown to have high potency against several oncology targets, including prostate cancer. 28945432 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker disease BEFREE Here, we synthesized a BBN-modified gadolinium oxide (Gd<sub>2</sub>O<sub>3</sub>) nanoprobe containing fluorescein (Gd<sub>2</sub>O<sub>3</sub>-5(6)-carboxyfluorescein [FI]-polyethylene glycol [PEG]-BBN) for targeted magnetic resonance (MR)/optical dual-modality imaging of PC. 28979118 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 AlteredExpression disease BEFREE A truncated version of the CCN1/CYR61 gene promoter, tCCN1-Prom, was more active than progression elevated gene-3 promoter (PEG-Prom) in regulating transformation-selective transgene expression in CaP and oncogene-transformed rat embryo cells. 25926554 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 AlteredExpression disease BEFREE The efficacy of the PEG-Prom as part of a cancer gene therapeutic regimen is further documented by in vivo experiments in which PEG-Prom-controlled expression of an apoptosis-inducing gene completely inhibited prostate cancer xenograft growth in nude mice. 15647352 2005